Valion Bio, Inc. VBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -61.28% | -49.63% | -58.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -61.28% | -49.63% | -58.49% |
| Cost of Revenue | -- | -- | -18.94% | -0.14% | -37.61% |
| Gross Profit | -- | -- | -160.17% | -256.10% | -162.90% |
| SG&A Expenses | -- | -- | 50.71% | -15.24% | -29.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 76.45% | 0.38% | -19.44% |
| Operating Income | -- | -- | -76.45% | -10.26% | 10.69% |
| Income Before Tax | -- | -- | -78.81% | -10.90% | 11.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -78.81% | -10.90% | 11.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -56.99% | -16.90% | 6.06% |
| EBIT | -- | -- | -76.45% | -10.26% | 10.69% |
| EBITDA | -- | -- | -76.46% | -10.32% | 10.69% |
| EPS Basic | -- | -- | -10.61% | -152.26% | -- |
| Normalized Basic EPS | -- | -- | -80.09% | -139.50% | -- |
| EPS Diluted | -- | -- | -10.61% | -152.26% | -- |
| Normalized Diluted EPS | -- | -- | -80.09% | -139.50% | -- |
| Average Basic Shares Outstanding | -- | -- | 505.75% | 793.15% | -- |
| Average Diluted Shares Outstanding | -- | -- | 505.75% | 793.15% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |